START FREE TRIAL

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Is Eli Lilly’s Orna Acquisition About RNA Or Something MUCH BIGGER?

Eli Lilly’s move to acquire Orna Therapeutics landed quietly, framed as another pipeline add-on in a year already defined...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Ascendis Pharma Becomes M&A Target Again—European Suitors In Play?

Ascendis Pharma (NASDAQ:ASND) has suddenly become one of the hottest tickers in biotech circles after its shares surged 7.5%...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...